Phase I/II trial of a cox-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: Radiation therapy oncology group 0213

Clinical Lung Cancer

Volumn 12, Issue 2, 2011, Pages 125-130

  Gore, Elizabeth ^a   Bae, Kyounghwa ^b   Langer, Corey ^c   Extermann, Martine ^d   Movsas, Benjamin ^e   Okunieff, Paul ^f   Videtic, Gregory ^g   Choy, Hak ^h  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b RTOG   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e HENRY FORD HOSPITAL   (United States)

^f UNIVERSITY OF ROCHESTER   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Celecoxib; Locally advanced non small cell lung cancer; Poor prognosis; PS2

Indexed keywords

CELECOXIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HUMAN; INFECTION; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SKIN TOXICITY; TREATMENT DURATION;

EID: 79959357812     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.03.007     Document Type: Article

References (39)

1. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III nonsmall- cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88:1210-5. (Pubitemid 26302034)
2. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advance, unresectable non-small cell lung cancer. J Natl Cancer Inst 1995; 87:198-205.
3. Curran WJ, Scott C, Langer C, et al. Phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) 9410. Lung Cancer 2000; 29:93.
4. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17:2692-9. (Pubitemid 29415225)
5. Nguyen LN, Komaki R, Allen P, et al. Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prog-nostic factors without distant metastasis: a retrospective review. Int J Radiat Oncol Biol Phys 1999; 44:1053-6. (Pubitemid 29342906)
6. Abratt RP, Shepherd LJ, Salton DG, et al. Palliative radiation for stage 3 non-small cell lung cancer-a prospective study of two moderately high dose regimens. Lung Cancer 1995; 13:137-43.
7. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cylcooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58:3761-4. (Pubitemid 28405625)
8. Soslow RA, Dannenberg AJ, Rush D, et al. Cox-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer 2000; 89:2637-45. (Pubitemid 32011609)
9. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58:4997-5001. (Pubitemid 28521147)
10. Steinauer KK, Gibbs I, Ning S, et al. Radiation induces upregulation of cyclooxygenase- 2 (COX-2) protein in PC-3 cells. Int J Radiat Oncol Biol Phys 2000; 48: 325-8.
11. Milas L, Kishi K, Hunter N, et al. Enhancement of tumor response to gammaradiation by an inhibitor of cylcooxygenase-2 enzyme. J Natl Cancer Inst 1999; 91:1501-4. (Pubitemid 29424556)
12. Kishi K, Petersen S, Petersen C, et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000; 60:1326-31. (Pubitemid 30152002)
13. Charlson ME, Pompei P, Ales K, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83. (Pubitemid 17055592)
14. Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burdent in geropsychiatric practice and research: application of cumulative illness rating scale. Psychiatry Res 1992; 41:237-48.
15. Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function. JAMA 1963; 185:914-9.
16. Lawton MP. Scales to measure competence in everyday activities. Psychopharmacol Bull 1988; 24:609-14. (Pubitemid 19054365)
17. Sheikh JJ, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. In: Brink TL, ed. Clinical Gerontology: A Guide to Assessment and Intervention. New York: Haworth Press; 1986:165-73. (Pubitemid 17221439)
18. Hollen PJ, Gralla RJ, Kris MG, et al. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 1993; 29(suppl 1):S51-8. (Pubitemid 23021152)
19. Hollen PJ, Gralla RJ, Kris MG, et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies: Psychometric assessment of the Lung Cancer Symptom Scale (LCSS). Cancer 1994; 73:2087-98. (Pubitemid 24107963)
20. Hollen PJ, Gralla RJ, Kris MG, et al. Quality of life during clinical trials: Conceptual model for the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 1994; 2:213-22.
21. Kaplan EL, Meier P. Nonparameteric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
22. Jennison C, Turnbull BW. Repeated confidence intervals for the median survival time. Biometrika 1985; 72:619-25.
23. Liao Z, Komaki R, Milas L, et al. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/ unresectable non-small cell lung cancer. Clin Cancer Res 2005; 11:3342-8. (Pubitemid 40627885)
24. De Ruysscher D, Bussink J, Rodrigus P, et al. Concurrent celecoxib versus placebo in patients with stage II-III non-small cell lung cancer: A randomized phase II trial. Radiother Oncol 2007; 84:23-5. (Pubitemid 47030688)
25. Mutter R, Lu G, Carbone DP, et al. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res 2009; 15:2158-65.
26. Csiki I, Morrow JD, Sandler A, et al. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: A phase II trial of celecoxib and docetaxel. Clin Cancer Res 2005; 11:6634-40. (Pubitemid 41339004)
27. Edelman MJ, Watson D, Wang X, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib-chemotherapy-Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008; 26:848-55. (Pubitemid 351398075)
28. Fidler JH, Argiris A, Patel JD, et al. The potential predictive value of cyclooxygenase- 2 expression and increased risk of gastrointestinal hemorrhage in advanced nonsmall cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res 2008; 14:2088-94. (Pubitemid 351551120)
29. Lau DH, Crowley JJ, Gandara DR, et al. Southwestern Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III nonsmall cell lung cancer. J Clin Oncol 1998; 16:3078-81. (Pubitemid 28417429)
30. Lau DH, Ryu JK, Gandara DR, et al. Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small cell lung carcinoma: A pilot study. Int J Radiat Oncol Biol Phys 1997; 38:157-61. (Pubitemid 27270956)
31. Davies AM, Chansky K, Lau DH, et al. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small cell lung cancer: SWOG phase II trial (S9712). J Clin Oncol 2006; 24:5242-6. (Pubitemid 46631368)
32. Werner-Wasik M, Scott C, Cox JD, et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced nonsmall cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000; 48:1475-82.
33. Movsas B, Scott C, Sause W, et al. The benefit of treatment intensification is age and histology dependent in patients with locally advanced non-small cell lung cancer (NSCLC): A quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 1999; 45: 1143-9.
34. Schild SE, Stella PJ, Geyer SM, et al. The outcome of combined-modality therapy for stage III non-small cell lung cancer in the elderly. J Clin Oncol 2003; 21:3201-6. (Pubitemid 46606250)
35. Scott C, Sause W, Byhardt RW, et al. Recursive partitioning analysis of 1592 patients on four Radiation Therapy Oncology Group studies in inoperable nonsmall cell lung cancer. Lung Cancer 1997; 17(suppl 1):S59-74.
36. Firat S, Byhardt RW, Gore E, et al. Comorbidity and Karnofsky performance score are independent prognostic factors in stage III non-small cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Int J Radiat Oncol Biol Phys 2002; 54:357-64. (Pubitemid 35286798)
37. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16:1582-7. (Pubitemid 28175784)
38. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus veinorelbine alone in elderly pateints with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18:2529-36. (Pubitemid 30432518)
39. Simon G, Extermann M, Chiappori A, et al. Phase 2 trial of decetaxel and geftitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer 2008; 112:2021-9. (Pubitemid 351574078)